Assessment of Eloquent Function in Brain Tumor Patients

This observational study is looking at how well different brain mapping techniques can identify important brain functions (like speech or movement) in people with brain tumors. Researchers will use brain mapping (a diagnostic test that shows brain activity) before, during, and after surgery to see how these functions are affected by the tumor and its removal. The study aims to understand how the brain reorganizes itself after surgery. You may be able to join if you are 19 or older, have a primary or metastatic brain tumor in or near an "eloquent" brain region (an area responsible for important functions), and are able to participate in mapping procedures. The main goal is to measure your brain function one year after surgery.

Study design
This is an observational study planning to enroll 75 participants. It does not involve new treatments but rather observes how existing diagnostic tools work.
What's involved
You would undergo pre-operative evaluations including clinical exams, neuropsychological tests, MRI, fMRI, DTI, and MEG studies. During surgery, awake mapping will be performed. Post-surgery, you'll have routine follow-up, and repeat neuropsychological testing and mapping studies at 2 and 6 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for at least one year, with brain function measured at that time.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01535430

Assessment of Eloquent Function in Brain Tumor Patients

Recruiting
Not specifiedAges 19+Observational
University of Nebraska
~75 participants
Updated 2026-01-13 on ClinicalTrials.gov
What's tested:Brain mapping

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Eloquent function
Measured over 1 year
Primary Brain Tumor
Metastatic Brain Tumor
1 sites across 1 states
Nebraska1
  • Michele Aizenberg, MD · PRINCIPAL_INVESTIGATOR · University of Nebraska

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

19 years and older
Brain tumor in or near eloquent brain regions that is appropriate for attempted resection
Appropriate body habitus and mental status/capacity to participate with non-invasive or invasive mapping
Benign or malignant intra-axial brain tumor
Primary or metastatic intra-axial brain tumor

Exclusion

Any contraindication to MRI (i.e. implanted devices)
Inappropriate body habitus or mental status/capacity to participate with non-invasive or invasive mapping in a safe and reliable manner
Declining to participate
Lacks capacity to understand the study or consent for themselves
Neurologic status which precludes testing (poor function- not testable)
Positive pregnancy test
End stage renal disease or severe renal dysfunction
  • Eloquent function1 year

    The location of the eloquent function of interest (motor, sensory, speech) will be assessed pre-operatively and intra-operatively and compared. Then, at 2 and 6 months post-operatively, repeat non-invasive mapping studies will be performed to compare to the subjects' prior studies. This will allow for assessment of reorganization and plasticity of function. Additionally, novel ways of identifying eloquent brain regions will be developed.